resistance to clopidogrel among iranian patients undergoing angioplasty intervention

نویسندگان

mohammad hajiaghajani department of cardiology, imam hussein medical and educational center, shahid beheshti university of medical sciences, tehran, iran.

farzad kobarfard department of medical chemistry, school of pharmacy, shahid beheshti university of medical sciences, tehran, iran.

olia safi department of clinical pharmacy, school of pharmacy, shahid beheshti university of medical sciences, tehran, iran.

kourosh sheibani clinical research and development center, imam hussein medical center, shahid beheshti university of medical sciences, tehran, iran.

چکیده

to study the resistance to standard dosage of clopidogrel among iranian patients following percutaneous coronary intervention measured by platelet aggregation test.patients undergoing percutaneous coronary intervention in imam hussein medical center, tehran, iran, who were under treatment with aspirin, but had no history of clopidogrel usage, entered the study. patients received standard dosage of clopidogrel (plavix®, sanofi, france, 600 mg loading dose and 75 mg/day afterward). platelet aggregation was measured using light transmission aggregometer. the response to the drug was categorized as complete resistance (platelet aggregation decreased less than 10%), intermediate resistance (platelet aggregation decreased between 10 to 30%) and complete response (platelet aggregation decreased to 30% or more). all patients were evaluated for major adverse cardio vascular events one month after the angioplasty based on mace criteria by phone contact.thirty-one patients with a mean age of 59 ± 13 entered the study. sixty-five percent of patients showed complete response to clopidogrel (95% ci: 45% to 81%), 22% showed intermediate resistance (95% ci: 10-41%) and 13% showed complete resistance (95% ci: 4-30%). one month after the angioplasty, no major adverse cardiovascular event was recorded.based on our findings, it seems that there is no major difference between iranian population and other studies regarding the resistance to clopidogrel. due to the limited number of participants in our study, further investigations with higher number of patients are recommended to more precisely calculate the percentage of resistance among iranian patients.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention

To study the resistance to standard dosage of clopidogrel among Iranian patients following percutaneous coronary intervention measured by platelet aggregation test.Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who were under treatment with aspirin, but had no history of clopidogrel usage, entered the study. Patients received standard dosage...

متن کامل

Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention

To study the resistance to standard dosage of clopidogrel among Iranian patients following percutaneous coronary intervention measured by platelet aggregation test.Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who were under treatment with aspirin, but had no history of clopidogrel usage, entered the study. Patients received standard dosage...

متن کامل

Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention

To study the resistance to standard dosage of clopidogrel among Iranian patients following percutaneous coronary intervention measured by platelet aggregation test. Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who were under treatment with aspirin, but had no history of clopidogrel usage, entered the study. Patients received standard dosag...

متن کامل

Clopidogrel Resistance and its Impact on Clinical Outcome of Iranian Patients Undergoing Percutaneous Coronary Intervention

The aim of current study was evaluating the frequency of clopidogrel resistance and its impact on clinical outcome of patients in Iranian patients. Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who received standard dosage of clopidogrel (Plavix®, Sanofi, France, 600 mg loading dose and 75 mg/day afterward) were recruited. Platelet aggregat...

متن کامل

Clopidogrel Resistance and its Impact on Clinical Outcome of Iranian Patients Undergoing Percutaneous Coronary Intervention

The aim of current study was evaluating the frequency of clopidogrel resistance and its impact on clinical outcome of patients in Iranian patients. Patients undergoing percutaneous coronary intervention in Imam Hussein Medical center, Tehran, Iran, who received standard dosage of clopidogrel (Plavix®, Sanofi, France, 600 mg loading dose and 75 mg/day afterward) were recruited. Platelet aggregat...

متن کامل

Association of ABCB1 Gene Polymorphisms and Clopidogrel Responsiveness in Iranian Patients undergoing Percutaneous Coronary Intervention

Clopidogrel is an antiplatelet agent currently used for preventing stent thrombosis. Despite certain clinical benefits of clopidogrel in patients undergoing percutaneous coronary intervention (PCI), adequate antiplatelet effect has not been obtained in some patients. The present study was designed to investigate the potential association of ABCB1 (ATP-Binding Cassette, Subfamily B, member1) gen...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
the iranian journal of pharmaceutical research

جلد ۱۲، شماره Supplement، صفحات ۱۶۹-۱۷۴

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023